This review aims to summarize the current knowledge on drugs used in adjuvant, neoadjuvant and palliative chemotherapy, hormone therapy, anti-HER2 drugs, CDK4/6 inhibitors, PARP (poly ADP-ribose polymerase) inhibitors, and immune therapy in breast cancer patients undergoing HD and PD. Here, ERBB2 is linked to breast carcinoma.